Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.

Zero of nine patients given <2 mg/m SP 2 sp BID of omacetaxine developed rash, but rash occurred in six of 10 patients receiving 2 mg/m SP 2 sp BID, and in both patients receiving 3 mg/m SP 2 sp BID. As apoptosis was prominent, cFLIP expression was examined in patient skin biopsies and a cell line treated with the component drugs of the AML-02 regimen. [Extracted from the article]